‘Race for the Cure’ Adds Nine New Sites

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

DALLAS--The Susan G. Komen Breast Cancer Foundation, producer of the country’s largest series 5K runs known as Race for the Cure, today announced nine new race sites for the 1998 series, bringing the total number of run/fitness walks to 86. Sites added include Austin, Texas; Evansville, Indiana; Grand Rapids, Michigan; Greeley, Colorado; Madison, Wisconsin; Richmond, Virginia; San Antonio, Texas; Thibodaux, Louisiana; and Tupelo, Mississippi.

DALLAS--The Susan G. Komen Breast Cancer Foundation, producer of the country’s largest series 5K runs known as Race for the Cure, today announced nine new race sites for the 1998 series, bringing the total number of run/fitness walks to 86. Sites added include Austin, Texas; Evansville, Indiana; Grand Rapids, Michigan; Greeley, Colorado; Madison, Wisconsin; Richmond, Virginia; San Antonio, Texas; Thibodaux, Louisiana; and Tupelo, Mississippi.

More than 500,000 runners and walkers are expected to participate in 1998’s Race for the Cure. In 1997, more than 445,000 runners and walked participated in the national series, representing a 37% increase over 1996.

Proceeds from the race go to both national research efforts and local breast cancer initiatives. "What truly sets the Komen Foundation apart is its depth on a community level," said Nancy Brinker, president and founder.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.